Biomerieux, Inc.

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Curie

Biomerieux Sa

Nicole Battail-Poirot

Jean-Philippe Charrier

Colette Jolivet-Reynaud

Genevieve Choquet-Kastylevsky

Corinne Beaulieu

Hervé Perron

Monique Arpin

Mylene Lesenechal

Geneviève Choquet-Kastylevsky

Anne Eveno-Nobile

Laurence Becquart

Jacques Portoukalian

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

I-Plastin assay method for the in vitro diagnosis of colorectal cancer

The present invention relates to a monoclonal antibody capable of binding to a wild-type HBsAg antigen and to at least one, preferably at least two and advantageously more than two, mutant forms of the HBsAg antigen, said monoclonal antibody binding to a peptide sequence consisting of at least 6 contiguous amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding to the peptide sequence constituted by the 199-208 region of the HBsAg antigen.

Monoclonal antibodies directed against hepatitis B viruses

The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.

Method of isolating cytotoxic heterocomplex associated with multiple sclerosis

Growing community of inventors

Lyons, France

Nicole Battail-Poirot